Edition:
India

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

56.63USD
13 Dec 2017
Change (% chg)

$1.76 (+3.21%)
Prev Close
$54.87
Open
$54.55
Day's High
$56.85
Day's Low
$54.08
Volume
737,963
Avg. Vol
604,523
52-wk High
$56.85
52-wk Low
$11.42

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

13 Dec 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

24 Nov 2017

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

10 Nov 2017

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

08 Nov 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

26 Aug 2017

BRIEF-Nektar Therapeutics Q2 loss per share $0.39

* Nektar therapeutics reports financial results for the second quarter of 2017

09 Aug 2017

BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358

* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy

24 Jul 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

21 Jul 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,274 +64.00
Eisai Co., Ltd (4523.T) ¥6,842 -22.00
NOF CORPORATION (4403.T) ¥2,983 +39.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,310.65 +49.95
Novo Nordisk A/S (NOVOb.CO) kr.335.40 -1.90
Pfizer Inc. (PFE.N) $36.64 +0.06
Novartis AG (NOVN.S) CHF83.90 +0.05
Roche Holding Ltd. (ROG.S) CHF241.90 +0.20
Roche Holding Ltd. (RO.S) CHF243.70 +0.50
GlaxoSmithKline plc (GSK.L) 1,306.50 -7.50

Earnings vs. Estimates